A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction

NCT02992288 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

427

Enrollment

INDUSTRY

Sponsor class

Conditions

Heart Failure

Interventions

DRUG: Neladenoson bialanate (BAY1067197)
DRUG: Neladenoson bialanate (BAY1067197)
DRUG: Neladenoson bialanate (BAY1067197)
DRUG: Neladenoson bialanate (BAY1067197)
DRUG: Neladenoson bialanate (BAY1067197)
DRUG: Placebo

Sponsor

Bayer